{"classes":[{"categories":[{"measurements":[{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"42.1","upperLimit":"NA","value":"NA"},{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"543"},{"groupId":"OG001","value":"528"}],"units":"Participants"}],"description":"DFS per IRF was defined as the time from CR to disease progression as determined by an IRF or to death from lymphoma or acute toxicity from treatment. CR was defined as disappearance of all evidence of disease.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"MEDIAN","populationDescription":"The ITT included all participants randomized to treatment. The ITT population where participants achieved CR.","reportingStatus":"POSTED","timeFrame":"From CR until PD or death (approximately up to 4 years)","title":"Disease-free Survival (DFS) Per IRF","type":"SECONDARY","unitOfMeasure":"months"}